Your browser is no longer supported. Please, upgrade your browser.
Cogent Biosciences, Inc.
Index- P/E- EPS (ttm)-6.53 Insider Own4.47% Shs Outstand9.85M Perf Week-13.85%
Market Cap502.07M Forward P/E- EPS next Y-1.27 Insider Trans0.00% Shs Float- Perf Month-18.33%
Income-61.20M PEG- EPS next Q-0.55 Inst Own36.90% Short Float- Perf Quarter-16.60%
Sales23.20M P/S21.64 EPS this Y24.70% Inst Trans112.82% Short Ratio2.94 Perf Half Y-29.50%
Book/sh-2.25 P/B- EPS next Y68.30% ROA-94.40% Target Price- Perf Year196.12%
Cash/sh- P/C- EPS next 5Y- ROE-448.70% 52W Range1.18 - 14.88 Perf YTD-30.19%
Dividend- P/FCF- EPS past 5Y- ROI-101.20% 52W High-47.31% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low564.41% ATR0.62
Employees72 Current Ratio6.60 Sales Q/Q-70.00% Oper. Margin- RSI (14)26.62 Volatility7.11% 6.76%
OptionableNo Debt/Eq- EPS Q/Q-226.20% Profit Margin- Rel Volume0.70 Prev Close8.20
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume516.12K Price7.84
Recom1.20 SMA20-16.26% SMA50-27.23% SMA200-14.28% Volume363,265 Change-4.39%
Dec-23-20Initiated Piper Sandler Overweight $22
Oct-14-20Initiated Ladenburg Thalmann Buy $4
Feb-22-21 07:00AM  
Feb-18-21 07:00AM  
Feb-11-21 07:00AM  
Dec-04-20 05:16PM  
Dec-01-20 11:08PM  
Nov-30-20 04:01PM  
Nov-20-20 07:00AM  
Nov-18-20 09:00AM  
Nov-12-20 04:30PM  
Nov-09-20 07:00AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Apr-01-20 01:42AM  
Nov-13-19 06:22PM  
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a A'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.